Monocyte enrichment from leukapharesis products for the generation of DCs by plastic adherence, or by positive or negative selection

被引:41
作者
Felzmann, T [1 ]
Witt, V [1 ]
Wimmer, D [1 ]
Ressmann, G [1 ]
Wagner, D [1 ]
Paul, P [1 ]
Hüttner, K [1 ]
Fritsch, G [1 ]
机构
[1] St Anna Childrens Hosp, Childrens Canc Res Inst, A-1090 Vienna, Austria
关键词
tumor vaccination; magnetic beads separation; monoclonal antibodies;
D O I
10.1080/14653240310003053
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background DCs for use in immunotherapy are frequently generated from peripheral blood monocytes. However, there are different approaches to monocyte enrichment. Method Plastic adherence is a widely used method for the enrichment of monocytes collected in a leukapheresis procedure. Alternatively, monocytes may be enriched by positive selection using magnetic beads coupled to CD14 Abs, or by cell depletion using beads coupled to Abs against CD2 and CD19 to remove non-monocytes. Results Positive selection resulted in the highest purity of immature DCs (97 +/- 1%), but in a low yield (8 +/- 3%). In contrast, depletion of non-monocytes gave a good yield (21 +/- 6%), but insufficient purity (42 +/- 10%). Conventional adherence procedures resulted in a good yield (25 +/- 5%) <LF>and reasonable purity (72 +/- 4%). All three monocyte enrichment procedures resulted in DCs that underwent maturation upon exposure to a combination of lipopolysaccharide and IFN-gamma. These DCs had a typical immune phenotype, they released similar amounts of IL-12, and had the capacity to support MLR.
引用
收藏
页码:391 / 398
页数:8
相关论文
共 13 条
[1]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[2]   Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood [J].
Bender, A ;
Sapp, M ;
Schuler, G ;
Steinman, RM ;
Bhardwaj, N .
JOURNAL OF IMMUNOLOGICAL METHODS, 1996, 196 (02) :121-135
[3]  
CHEN WJ, 1994, J IMMUNOL, V152, P3991
[4]   Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells [J].
Dhodapkar, MV ;
Steinman, RM ;
Sapp, M ;
Desai, H ;
Fossella, C ;
Krasovsky, J ;
Donahoe, SM ;
Dunbar, PR ;
Cerundolo, V ;
Nixon, DF ;
Bhardwaj, N .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :173-180
[5]   Dendritic cells as adjuvants in antitumor immune therapy [J].
Felzmann, T ;
Gadner, H ;
Holter, W .
ONKOLOGIE, 2002, 25 (05) :456-464
[6]   Functional maturation of dendritic cells by exposure to CD40L transgenic tumor cells, fibroblasts or keratinocytes [J].
Felzmann, T ;
Buchberger, M ;
Lehner, M ;
Printz, D ;
Kircheis, R ;
Wagner, E ;
Gadner, H ;
Holter, W .
CANCER LETTERS, 2001, 168 (02) :145-154
[7]  
GADD SJ, 1994, IMMUNOLOGY, V81, P611
[8]   Dendritic cell regulation of TH1-TH2 development [J].
Moser, M ;
Murphy, KM .
NATURE IMMUNOLOGY, 2000, 1 (03) :199-205
[9]   Mature myeloid dendritic cells for clinical use prepared from CD14+ cells isolated by immunomagnetic adsorption [J].
Padley, DJ ;
Dietz, AB ;
Gastineau, DA ;
Vuk-Pavlovic, S .
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2001, 10 (03) :427-429
[10]   Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization [J].
Regnault, A ;
Lankar, D ;
Lacabanne, V ;
Rodriguez, A ;
Théry, C ;
Rescigno, M ;
Saito, T ;
Verbeek, S ;
Bonnerot, C ;
Ricciardi-Castagnoli, P ;
Amigorena, S .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 189 (02) :371-380